 Following the recent pullback in Inovio Pharmaceuticals Inc.s NASDAQ:INO shares, the stock valuation seems to have been stripped of most of the remaining COVID-19 value, according to BofA Securities. The Inovio Pharmaceuticals Analyst: Geoff Meacham upgraded the rating for Inovio Pharmaceuticals from Underperform to Neutral while raising the price target from 8 to 10. 